CA-SCIENTIST.COM
11.7.2024 13:56:27 CEST | Business Wire | Press release
BioPharmCatalyst (BPC), a division of Scientist.com, today announced that members with an “Elite” and “Elite Plus” subscription now get full access to Trial Insights, which curates and enriches publicly available data from clinicaltrials.gov and other data sources. Trial Insights creates filterable, customizable dashboards on clinical trial status, sponsors and new medicines, enabling investors to make smarter, data-driven decisions.
“The ability to track drugs throughout their development cycle based on catalyst events not only drives biotech investor decision making, but also helps scientists keep up to date with clinical trials in their research areas,” stated John Gagliano, Senior Director, BioPharmCatalyst. “The addition of Trial Insights provides subscribers with real time insight into clinical trial results that were previously difficult and time consuming to gather through publicly available sources.”
BPC equips investors in the biotech and pharmaceutical industries with a comprehensive suite of tools for making informed investment decisions. These include an FDA calendar, a PDUFA calendar, an earnings calendar, the latest IPO information and a company’s cash database. With Trial Insights, Elite and Elite Plus subscribers can closely monitor ongoing clinical trials being conducted around the world in real time through their existing account.
To access BioPharmCatalyst’s investing tools and start a free trial, visit www.biopharmcatalyst.com. To learn more about Trial Insights, visit www.biopharmcatalyst.com/trial-insights.
About Scientist.com
Scientist.com is the world's leading AI-enabled marketplace for scientific research. The marketplace simplifies drug discovery research, saving time and money and providing access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 100 biotechnology companies and the US National Institutes of Health (NIH).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711495417/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Digital Trust Index 2026: AI Skepticism and Identity Access Friction Are Costing Revenue31.3.2026 14:00:00 CEST | Press release
93% of IT leaders are deploying GenAI, but only 23% of consumers trust companies that use AI to handle their data. Friction at sign-up, login, and onboarding is causing customer abandonment and revenue loss, with 68% of consumers switching due to website issues. 69% of consumers trust companies more when MFA (multi factor authentication) is used, 68% say the same about passkeys. Thales today released the 2026 Digital Trust Index, one of the most comprehensive global studies of digital trust. Surveying more than 15,000 consumers, business partners, and IT decision makers across 13 industries, the research reveals that digital trust is won or lost during sign-up, login, and throughout the lifecycle of personal data handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331668723/en/ Beyond banking’s clear lead, the rest of the sectors fall well behind in consumer confidence. ©Thales Consumer Trust is Won or Lost at Login
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients31.3.2026 14:00:00 CEST | Press release
Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products for gastrointestinal cancers, have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis (FAP) through an Early Access / Named Patient Program. FAP is characterized by a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option, and surgical resection remains the standard of care. eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor involved in cellular metabolism, growth, and proliferation and activated during tumorigenesis. mTOR has been shown to be over-expressed in FAP polyps, supporting the rationale for its use in treatment. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa
SLB and Azule Energy Scale Enterprise Digital Operations to Strengthen Energy Delivery in Angola31.3.2026 14:00:00 CEST | Press release
SLB’s enterprise digital platform will enhance execution reliability across Azule’s operations in Angola Global technology company SLB (NYSE: SLB) today announced a three-year agreement with Azule Energy to continue and expand the use of its enterprise digital platform across Azule’s operations in Angola. The platform will help Azule drive more consistent execution, accelerate decision-making, and support reliable energy delivery across its portfolio. Azule Energy — a joint venture of bp and Eni and the largest independent energy producer in Angola — operates some of the region’s most complex assets. The agreement builds on two years of Delfi™ use within Azule’s reservoir organization, where the platform supports reservoir studies, modelling, simulation, and well planning workflows, and supports enterprise-scale digital integration by connecting reservoir workflows with broader operational data environments over time. “Azule operates large, complex energy assets where execution reliabi
Esri and RoboGarden Sign Strategic MOU to Advance Geospatial and Geomatics Education31.3.2026 14:00:00 CEST | Press release
Agreement Explores New Models for Digital Learning, Academic Collaboration, and Global Workforce Readiness Esri and RoboGarden have signed an MOU to explore strategic collaboration that broadens access to modern GIS and geomatics education. RoboGarden, a Canadian EdTech company, offers gamified and scalable digital learning solutions for academic institutions, governments, and industry. The MOU outlines joint exploration of academic pathways, improved regional coordination, and potential creation of a Geospatial & Geomatics Virtual Academy. The agreement focuses on enhancing digital learning delivery, expanding localized e-learning opportunities, and supporting global workforce development in high-demand technology fields. To stay informed about Esri’s education initiatives and resources, visit esri.com/en-us/industries/education/overview. Esri, the global leader in geographic information system (GIS) technology, today announced the signing of a Memorandum of Understanding (MOU) with R
ExaGrid Named a Finalist for the Network Computing Awards 202631.3.2026 14:00:00 CEST | Press release
ExaGrid nominated in 11 Categories for annual industry awards ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 11 categories for the annual Network Computing Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331887370/en/ ExaGrid has become a finalist in the following categories: Data Protection Product of the Year The Return On Investment Award Air Gapped Ransomware Recovery Product of the Year Storage Product of the Year Hardware Product of the Year The Customer Service Award Enterprise Product of the Year New Product of the Year Product of the Year Company of the Year Additionally, ExaGrid is nominated for the “Bench Tested Product of the Year” award determined by judges after an independent product review of the ExaGrid Tiered
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom